Home › Compound Library › Lurasidone (Latuda)

Lurasidone (Latuda)

Antipsychoticprescriptionoral · inferred

Benzisothiazol atypical antipsychotic with high affinity for D2, 5-HT2A, and 5-HT7 receptors and moderate alpha-2c antagonism. Uniquely low affinity for H1 and 5-HT2C receptors, resulting in minimal weight gain and metabolic effects compared to other atypicals. Must be taken with food (≥350 calories) — bioavailability doubles with food. Metabolized by CYP3A4; contraindicated with strong 3A4 inhibitors/inducers.

Projected serum levels — 40 mg, once daily

Lurasidone (Latuda)
Lurasidone (Latuda) modeled serum levels, 40 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Lurasidone (Latuda) modeled serum levels with a loading dose of 65.0 mg, then 40 mg once daily The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 40 mg once daily (oral).

Loading schedule: 65.0 mg on day 1, then 40 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 5.5 mg, trough ≈ 2.3 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antipsychotic
Route modeled
Oral
Model confidence
inferred
Half-life
18 h
Common dose
40 mg
Suggested maximum
160 mg/day
Reference dose range
20–160 mg (single dose)
Suggested cadence
once daily
Validated against
40 mg oral — Cmax 0.020 mg/L at 1.5 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Lurasidone (Latuda) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Lurasidone (Latuda) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Lurasidone (Latuda) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~5.00x

  • contraindicated
    Diltiazem + Lurasidone (Latuda) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Lurasidone (Latuda) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Lurasidone (Latuda) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Lurasidone (Latuda) AUC by ~10.00x

Serum checks 317 modeled interaction pairings for lurasidone (latuda) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Lurasidone for the treatment of bipolar depression: a 6-week, randomized, double-blind, placebo-controlled study (PREVAIL-2) Loebel A et al. · American Journal of Psychiatry, 2014 DOI

    Pivotal RCT establishing lurasidone 20-120 mg/day as effective monotherapy for bipolar I depression with significant MADRS improvement versus placebo and minimal weight gain (0.0-0.2 kg).

  2. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, fixed-dose, placebo-controlled trial Meltzer HY et al. · Neuropsychopharmacology, 2011 DOI

    Phase III RCT finding lurasidone 80 mg/day significantly reduced PANSS scores in acute schizophrenia versus placebo, with weight gain of only 0.4 kg and minimal metabolic effects.

2 published studies referenced in the app, each with a plain-language summary.